Rekor Systems, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Rekor Systems, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $9.23M | Mar 12, 2021 |
| FY2020 | Dec 31, 2019 | $5.47M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $20.05M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $22.14M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $12.13M | Apr 12, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $5.70M | Mar 12, 2021 |
| FY2020 | Dec 31, 2019 | $3.82M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $10.08M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $8.34M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $5.17M | Apr 12, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.46M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($61.41M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($45.69M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($83.12M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($26.78M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($14.18M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($15.88M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($5.70M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($5.04M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($39.0K) | Apr 12, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($28.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($54.32M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($42.12M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($85.78M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($31.83M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($11.85M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($7.53M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($5.12M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($4.64M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($93.9K) | Apr 12, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.60M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $18.77M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $18.27M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.62M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $8.29M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $3.19M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.43M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $131.0K | Mar 30, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $18.83M | Apr 11, 2019 |
| FY2018 | Dec 31, 2017 | $12.98M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $5.26M | Apr 12, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.37M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($32.47M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($32.63M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($39.61M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($18.03M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($15.06M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($21.33M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($2.05M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($3.17M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($136.1K) | Apr 12, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.39M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $82.48M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $92.15M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $83.84M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $125.88M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $40.40M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $28.99M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $18.06M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $20.60M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $5.48M | Apr 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.52M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $48.33M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $58.78M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $34.50M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $24.79M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $8.54M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $32.22M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $9.55M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.69M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $1.67M | Apr 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.87M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $34.14M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $33.37M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $49.34M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $101.09M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $25.19M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | ($9.04M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $3.46M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $6.51M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $1.55M | Apr 11, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.31M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $24.31M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $20.59M | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $20.59M | Mar 25, 2024 |
| FY2023 | Dec 31, 2021 | $53.45M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $6.34M | Mar 29, 2023 |
| FY2020 | Dec 31, 2019 | $6.34M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.40M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.09M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 12, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($291.55M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($260.09M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($198.68M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($153.00M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($69.88M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($43.05M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($28.41M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($12.06M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($5.83M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($430.4K) | Apr 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.57M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $15.39M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.92M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $25.80M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $20.60M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.08M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $2.07M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.96M | Apr 11, 2019 |
| FY2018 | Dec 31, 2016 | $2.79M | Apr 11, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.00M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $15.88M | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $26.02M | Mar 25, 2024 |
| FY2020 | Dec 31, 2020 | $1.97M | Mar 12, 2021 |
| FY2019 | Dec 31, 2019 | $20.41M | Mar 30, 2020 |
| FY2018 | Dec 31, 2018 | $3.43M | Apr 11, 2019 |
| FY2017 | Dec 31, 2017 | $1.41M | Apr 12, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
| FY2018 | Dec 31, 2018 | 0 | Apr 11, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 12, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Apr 11, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 12, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 136.48M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 104.54M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 69.18M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 54.41M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 43.99M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 33.01M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 21.60M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 18.77M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 14.46M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | 5.00M | Apr 12, 2018 |